Skip to main content
. Author manuscript; available in PMC: 2024 Jul 11.
Published in final edited form as: Immunity. 2023 May 25;56(7):1649–1663.e5. doi: 10.1016/j.immuni.2023.04.019

Figure 6. SIV Env-binding antibody titers wane in alloHSCT recipient macaques as T cell donor chimerism increases and remain low after ATI only in aviremic HSCT recipients.

Figure 6.

(A-D) Longitudinal plasma titers of SIV Env-binding antibodies in alloHSCT recipients (left axis, colored symbols) and time-matched controls (left axis, black symbols) from Figure 1, alongside blood CD3+ T cell donor chimerism in HSCT recipients (right axis, red traces). Colored dotted vertical lines indicate the day of HSCT for each recipient macaque. Asterisks indicate anti-CD20 depleting antibody administration in alloHSCT recipients. Gray boxes denote ART treatment. Vertical dashed lines indicate the timepoint of first detectable SIV plasma viral load for alloHSCT recipients (colored) and controls (black). Arrows indicate the first dose of anti-CD8α depleting antibody for alloHSCT recipients (colored) and controls (black). See also figure S6.